Australia markets closed
  • ALL ORDS

    7,288.80
    -36.60 (-0.50%)
     
  • ASX 200

    7,032.50
    -38.50 (-0.54%)
     
  • AUD/USD

    0.7126
    +0.0018 (+0.26%)
     
  • OIL

    91.63
    -2.71 (-2.87%)
     
  • GOLD

    1,817.30
    +10.10 (+0.56%)
     
  • BTC-AUD

    33,980.02
    -161.37 (-0.47%)
     
  • CMC Crypto 200

    576.20
    +4.92 (+0.86%)
     
  • AUD/EUR

    0.6941
    +0.0062 (+0.90%)
     
  • AUD/NZD

    1.1042
    -0.0006 (-0.05%)
     
  • NZX 50

    11,730.52
    -29.49 (-0.25%)
     
  • NASDAQ

    13,541.60
    +249.61 (+1.88%)
     
  • FTSE

    7,500.89
    +34.98 (+0.47%)
     
  • Dow Jones

    33,705.88
    +369.21 (+1.11%)
     
  • DAX

    13,795.85
    +101.34 (+0.74%)
     
  • Hang Seng

    20,175.62
    +93.19 (+0.46%)
     
  • NIKKEI 225

    28,546.98
    +727.65 (+2.62%)
     

Immunovant (IMVT) Set on Lead Candidate Batoclimab's Development

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Immunovant, Inc. IMVT is making good progress with the development of its lead pipeline candidate, batoclimab (formerly IMVT-1401), a fully human, monoclonal antibody that selectively binds to and inhibits neonatal fragment crystallizable receptor (FcRn).

The candidate is being developed for the treatment of several autoimmune diseases, with an initial focus on the treatment of myasthenia gravis (“MG”), thyroid eye disease (“TED”) and warm autoimmune hemolyticanemia (“WAIHA”).

The company is developing batoclimab as a fixed-dose subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.

Earlier this month, Immunovant achieved alignment with the FDA’s Division of Ophthalmology to initiate two phase III studies evaluating batoclimab for treating TED. The two placebo-controlled studies are expected to begin in the second half of 2022. Top-line data from both studies are expected in the first half of 2025.

Per the company, the potential success of said studies can support registration of batoclimab for TED.

Immunovant remains on track to initiate a pivotal phase III study to evaluate batoclimab for the treatment of MG by the end of June 2022. Top-line data from the same is expected in the second half of 2024.

The company is focused on continuing the development of batoclimab for MG, WAIHA and TED in the days ahead. It plans to evaluate potential new indications for batoclimab and announce two new indications by August 2022.

Shares of Immunovant have plunged 60.2% so far this year compared with the industry’s decrease of 27.4%.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

In the absence of a marketed drug, successful development of batoclimab remains the main focus of Immunovant. There is only one candidate in development in its pipeline. Also, batoclimab is still in late-stage development and is some years away from commercialization.

Immunovant‘s ability to generate sufficient revenues to achieve profitability will depend heavily on the successful development and eventual commercialization of batoclimab or any future candidate. Any developmental setback for batoclimab will be a major setback for the company, leaving an adverse impact on its shares.

Immunovant, Inc. Price and Consensus

Immunovant, Inc. Price and Consensus
Immunovant, Inc. Price and Consensus

Immunovant, Inc. price-consensus-chart | Immunovant, Inc. Quote

Zacks Rank & Stocks to Consider

Immunovant currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector are Leap Therapeutics, Inc. LPTX, AegleaBio Therapeutics, Inc. AGLE and Precision BioSciences, Inc. DTIL, all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 11.1% for 2022 and 5.9% for 2023 in the past 60 days.

Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.

Aeglea BioTherapeutics’ loss per share estimates narrowed 19.4% for 2022 and 37.6% for 2023 in the past 60 days.

Earnings of Aeglea BioTherapeutics have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. AGLE delivered an earnings surprise of 9.47%, on average.

Precision BioSciences’ loss per share estimates narrowed 21.7% for 2022 and 31.4% for 2023 in the past 60 days.

Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting